A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of AXA1665 in Subjects With Liver Cirrhosis and Prior Overt Hepatic Encephalopathy (EMMPOWER)
Latest Information Update: 22 May 2024
At a glance
- Drugs AXA 1665 (Primary)
- Indications Hepatic encephalopathy
- Focus Therapeutic Use
- Acronyms EMMPOWER
- Sponsors Axcella Health
- 12 Oct 2022 This trial has been completed in Spain (End Date: 6 July 2022) according to European Clinical Trials Database record.
- 09 Oct 2022 This trial has been completed in Poland (End Date: 6 July 2022) according to European Clinical Trials Database record.
- 26 May 2022 According to an Axcella Therapeutics media release, this is a rare disease of very ill patients with enrollment challenges and timelines to approval will be long; as a result, the Company has made the decision to terminate this trial.